Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL

Hare, Lucy; Burke, G A Amos; Turner, Suzanne D.

doi:10.3390/cancers13236003

Cited by 7 publications

(4 citation statements)

References 182 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among targeted therapies, brentuximab vedotin (BV), a CD30-directed antibody conjugated to the antitubulin agent monomethyl auristatin E (MMAE), represents a new therapeutic option, having shown a 53% overall response and manageable side effects when investigated as single agent in paediatric relapsed/refractory patients. 8,9 The prognostic role of minimal disseminated disease (MDD) in ALCL, measured by quantitative reverse transcription PCR (qRT-PCR), in peripheral blood (PB) has been extensively demonstrated. 10,11 In addition, the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) and Berlin-Frankfurt-Münster (BFM) groups demonstrated that the early evaluation of minimal residual disease (MRD) in NPM::ALK-positive ALCL identifies patients with a very high relapse risk and inferior survival.…”

Section: E T T E R T O T H E E D I T O Rmentioning

confidence: 99%

Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large‐cell lymphoma treated with brentuximab vedotin: A case series

Contarini,

Carraro,

Lovisa

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

Section: E T T E R T O T H E E D I T O Rmentioning

confidence: 99%

Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large‐cell lymphoma treated with brentuximab vedotin: A case series

Contarini,

Carraro,

Lovisa

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

“…8 Nevertheless, as for ALK-rearranged lung carcinomas, mechanisms of resistance may develop, including acquired ALK mutations. 18 Mutational profiling of ALK + ALCL has revealed NOTCH1 mutations in 20% of the cases. NOTCH1 expression is also induced via STAT3 activation mediated by the ALK fusion protein.…”

Section: Anaplastic Large Cell Lymphomas Alk-positivementioning

confidence: 99%

Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions

Bisig,

Savage,

De Leval

2023

haematol

View full text Add to dashboard Cite

Predominantly nodal is the most common clinical presentation of peripheral T- (and NK-) cell lymphomas (PTCL), which comprise three main groups of diseases: (i) systemic anaplastic large cell lymphomas (ALCL), whether positive or negative for anaplastic lymphoma kinase (ALK); (ii) follicular helper T-cell lymphomas (TFHL); and (iii) PTCL, not otherwise specified (NOS). Recent advances in the genomic and molecular characterization of PTCL, with enhanced understanding of pathobiology, have translated into significant updates in the latest 2022 classifications of lymphomas. ALK-negative ALCL is now recognized to be genetically heterogeneous, with identification of DUSP22 rearrangements in approximately 20-30% of cases, correlated with distinctive pathological and biological features. The notion of cell-of-origin as an important determinant of the classification of nodal PTCL is best exemplified by TFHL, considered as one disease or a group of related entities, sharing oncogenic pathways with frequent recurrent epigenetic mutations as well as a relationship to clonal hematopoiesis. Data are emerging to support that a similar cell-of-origin concept might be relevant to characterize meaningful subgroups within PTCL, NOS, based on cytotoxic and/or Th1 versus Th2 signatures. The small group of primary nodal Epstein-Barr virus-positive lymphomas of T- or NK-cell derivation, formerly considered PTCL, NOS, is now classified separately, due to distinctive features, and notably an aggressive course. This review summarizes current knowledge of the pathology and biology of nodal-based PTCL entities, with an emphasis on recent findings and underlying oncogenic mechanisms.

show abstract

“…Although rare, there have been several documented cases of ALK-positive pcALCL (pcALCL) diagnosed on skin biopsy without evidence of secondary systemic involvement. This paradox poses several challenges in the classification, prognostication, treatment, and follow-up of these patients (4,(7)(8)(9). Here we present a review of current literature regarding adult and pediatric ALK-positive ALCL without evidence of systemic involvement on initial diagnosis.…”

Section: Introductionmentioning

confidence: 97%

Challenges in utilizing ALK expression to distinguish primary cutaneous from systemic anaplastic large cell lymphoma

Gleason,

Afifi,

Banner

et al. 2024

Mol Clin Oncol

View full text Add to dashboard Cite

Anaplastic large cell lymphoma (ALCL) is a CD30 + peripheral T-cell lymphoma with a clinical spectrum including cutaneous and systemic presentations. While primary cutaneous ALCL (pcALCL) has a favorable prognosis, systemic ALCL (sALCL) has poorer survival outcomes. Expression of anaplastic lymphoma kinase (ALK) by malignant cells has been suggested to distinguish sALCL from pcALCL. However, there have been documented cases of ALK-positive ALCL confined to the skin. The present study reviewed characteristics of published cutaneous ALK-positive ALCL cases to distinguish between these two entities. In 23 identified adults with ALK-positive pcALCL, 26% developed systemic involvement and 74% had skin-limited disease. In 14 pediatric patients, 36% had both cutaneous and systemic involvement and 64% had cutaneous disease only. This analysis revealed that pcALCL and sALCL could not reliably be distinguished by ALK expression or nuclear vs. cytoplasmic localization. Localized treatment with frequent monitoring may be sufficient in ALK-positive pcALCL until there is evidence of progression. Physicians should be aware of the overall spectrum of ALCL, including cutaneous limited disease, systemic disease, disease with NPM-ALK translocation, disease with ALK positivity and disease with skin recurrence.

show abstract

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL

Cited by 7 publications

References 182 publications

Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large‐cell lymphoma treated with brentuximab vedotin: A case series

Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large‐cell lymphoma treated with brentuximab vedotin: A case series

Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions

Challenges in utilizing ALK expression to distinguish primary cutaneous from systemic anaplastic large cell lymphoma

Contact Info

Product

Resources

About